Navignostics' diagnostic technology contributed to improved outcomes in advanced melanoma patients

Navignostics today announced the publication of a landmark study in Nature Medicine showing that its single-cell diagnostic technology contributed to improved outcomes in advanced melanoma patients, particularly those with no remaining standard treatment options. The Tumor Profiler (TuPro) study, revealed that heavily pretreated patients (≥3 prior therapies) receiving individualized treatments informed by multiomics profiling on Navignostics’ platform achieved a 64.7% disease control rate, compared to just 23.5% in the matched cohort — a nearly threefold improvement. This group also experienced a median progression-free survival of 8.3 months, versus only 2.0 months for those treated without access to Navignostics data.

These findings demonstrate the clinical benefit of Navignostics’ proteomics-based tumor profiling approach, which combines spatial proteomics and functional biomarkers to inform personalized treatment decisions. The study showed that TuPro data — powered by Navignostics — influenced 75% of molecular tumor board decisions across the broader cohort, underscoring the platform’s potential to become a new standard in late-stage oncology care.

The study analyzed over 43,000 potential markers and 500GB of data per patient using a suite of nine cutting-edge technologies including spatial proteomics, single-cell sequencing, and drug phenotyping, all in a 4-week diagnostic loop. The high-resolution dataset derived using these combined techniques could enable the development of powerful AI models that uncover complex biological patterns, support personalized treatment decisions, and form the foundation for scalable, clinically relevant precision oncology tools.

The TuPro study is one of the first real-world validations of polymarker diagnostics in oncology, demonstrating clinical utility beyond outdated single-gene or protein approaches. In advanced stages of complex diseases like melanoma, where no single mutation reliably predicts treatment response, multiomics and functional profiling provide a systems-level view that can directly inform better treatment decisions and optimize healthcare resources.

"We see from this study that precision oncology can dramatically improve late-stage patient outcomes, but only when it’s informed by comprehensive tumor profiling that captures the full complexity of each individual cancer," said Dr. Jana Fischer, co-founder and CEO of Navignostics. "We’ve demonstrated not just technical feasibility, but clinical benefit — and we’ve already made this test available for early access."

Navignostics’ diagnostics are currently available for early research access for colorectal and lung cancer in Switzerland, with broader distribution via partner pathology labs scheduled for Q1 2026. Navignostics is now preparing to scale globally and is in active discussions with strategic partners and investors to expand into melanoma and pan-cancer diagnostics.